FAYETTEVILLE, NY, UNITED STATES, January 9, 2026 /EINPresswire.com/ — January is traditionally a peak period for pharmaceutical list price adjustments. The AnalySource team analyzed Wholesale ...

Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

At the JP Morgan Healthcare Conference (JPMHC), global pharmaceutical and biotech companies unveiled their research and ...

After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...

--Novo Nordisk is hunting for deals to widen its obesity portfolio, CEO Mike Doustdar told Bloomberg in an interview. "As ...

After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

Few celebrity chefs are as instantly recognisable as Gordon Ramsay, whose razor-sharp tongue and unforgiving food standards ...